ArticleFrontiers in pharmacology2025
Evaluating the risk of osteoporosis-related adverse events with proton pump inhibitors: a pharmacovigilance study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pharmacovigilance signals for congenital heart disease related to drug exposure: A disproportionality analysis based on the FAERS database.American heart journal plus : cardiology research and practice · 2026Article
- Real-world pharmacovigilance of drug-induced osteoporosis: a focus on antiretroviral therapy and toxicological mechanisms in the elderly.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Proton pump inhibitors (PPIs) are the most effective antacids and are widely used in the treatment of acid-related diseases. However, the impact of PPIs on bone remains controversial. This study aimed to explore the association between PPIs and osteoporosis-related adverse events in the real world. Materials and methods: Data from the United States Food and Drug Administration Adverse Event Reporting System from the first quarter of 2004 to the third quarter of 2024 were included in this study. Four pharmacovigilance analyses, reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and Empirical Bayes geometric mean (EBGM) were used to explore the association between PPIs use and osteoporosis-related adverse events. In addition, we used the Bonferroni corrected P values and 95% confidence interval (95%CI). Meanwhile, the situation of different age and gender groups was examined using subgroup analysis. Additionally, evoked times and Weibull distributions were used to analyze the data further. Results: At the Primary terms level, esomeprazole, omeprazole and pantoprazole were found to have positive adverse event signals. However, at the overall dimension level of Standardized Medical Dictionary for Regulatory Activities (MedDRA) query, only esomeprazole (ROR: 8.83, 95%CI: 8.53-9.13, P < 0.001) and omeprazole (ROR: 1.54, 95%CI: 1.44-1.66, P < 0.001) signals were positive. Based on subgroup stratification, the study showed that the signal intensity of adverse events was stronger among women and older adults. Weibull distribution analysis indicated that the incidence of osteoporosis-related adverse events of esomeprazole increased gradually over time, while the risk of omeprazole did not show regular spatial and temporal distribution. Conclusion: This study comprehensively reports the risk of osteoporosis in the clinical use of five commonly used PPIs, which provides certain ideas and insights for the clinical prevention of such adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.